Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Miles, David; Chan, Arlene; Dirix, Luc; Cortés, Javier; Pivot, Xavier; Tomczak, Piotr; Delozier, T.; Sohn, Joohyuk; Provencher, Louise; Puglisi, Fabio; Harbeck, Nadia; G. Steger, Guenther; Schneeweiß, Andreas; Wardley, Andrew; Chlistalla, A.; Romieu, Gilles

doi:10.1200/jco.2008.21.6457

Public

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Published in Journal of Clinical Oncology • May 25, 2010

Authors:

David Miles

Arlene Chan

Luc Dirix

Abstract

PURPOSE: The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. P...

Subject

Docetaxel

Medicine

Bevacizumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!